30 October 2026
TRex Bio (TRXB)
IPO 9 October 2026
The company
TRex Bio is a clinical-stage biotechnology company developing immunoregulatory medicines for autoimmune and inflammatory diseases. Its platform is based on the biology of tissue regulatory T cells, which help control immune responses within specific organs. The company expects topline data from the Phase 1b portion of its lead clinical program in mid-2027.
Competitors and market
TRex Bio competes with established immunosuppressive medicines and biotechnology companies developing targeted treatments for autoimmune and inflammatory diseases. Its approach seeks to deliver more tissue-specific immune regulation, potentially reducing the systemic effects associated with conventional therapies. The IPO raised less than $120 million, and the limited free float may contribute to volatility while investors await clinical evidence. The shares have traded mostly below the offer price, indicating that the market is assigning limited value to the platform before the 2027 data.
Price action
- IPO price: $14.00 per share, the bottom of its $14.00–16.00 range
- Offering size: 8,333,334 shares for gross proceeds of approximately $116.7 million
- First day, 9 October: traded as low as $13.50, below the IPO price
- Latest verified price: $13.52 at the 29 October close, down 6.3% for the session
- Performance from IPO price: approximately −3.4%
- Post-IPO range: $13.21–16.56
- Shares outstanding: approximately 27 million
- IPO free float: approximately 8.33 million shares
TRex Bio closed at $13.52 on 29 October, close to the lows of its first three weeks of trading. The shares rose above $15.50 on 21 and 22 October but did not hold those levels and returned below the $14 offer price, so the stock has not yet established clear support above the issue price.
Conclusion and what to expect
TRex Bio has a market capitalization of approximately $365 million at the 29 October close, but meaningful clinical data are not expected until mid-2027. The nearest potential catalyst is the 18 November quiet-period expiration and possible research initiations from J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow. The 180-day lock-up covering directors, executives and substantially all existing shareholders is expected to expire around 6 April 2027, although shares purchased by Eli Lilly are not covered by the underwriters’ restriction. Until clinical results arrive, the main risk is that continued trading below $14 weighs on investor interest after coverage begins.
Read more about TRXB.US on the TFOS platform
Iambic Therapeutics (IAM)
IPO 15 October 2026
The company
Iambic Therapeutics is a clinical-stage biotechnology company using artificial intelligence to discover and develop new medicines. Its lead candidate, IAM1363, is expected to advance through Phase 1 and into Phase 2/3 development using part of the IPO proceeds. The company is also developing IAM217 and IAM-C1 while investing in its proprietary AI-based drug-discovery platform.
Competitors and market
Iambic competes with traditional biotechnology companies and AI-focused drug developers seeking to improve the speed and probability of clinical development. Its investor base and relationships with technology companies, including Nvidia, provide credibility but do not eliminate normal clinical-development risk. The IPO priced at the midpoint of its range and attracted indicated interest from ARK Investment Management and Duquesne Family Office. Despite a strong debut, the shares subsequently fell below the offer price as the market reduced valuations across the AI-biotechnology sector.
Price action
- IPO price: $16.00 per share, the midpoint of its $15.00–17.00 range
- Offering size: 9,375,000 shares
- First day, 15 October: opened at $16.15, reached $19.70 and closed at $18.91, approximately 18.2% above the IPO price
- Latest verified price: $14.28 at the 29 October close, down 3.4% for the session
- Performance from IPO price: approximately −10.8%
- Performance from first-day close: approximately −24.5%
- Post-IPO range: $13.02–25.00, with the high on 16 October
Chart: trade.tfos.com/charts/IAM.US
Iambic recorded the weakest performance among the four companies that have traded for at least a week. The latest price was near the bottom of its post-IPO range, suggesting that early institutional interest has not provided lasting support.
Conclusion and what to expect
Iambic generated $12.8 million in first-half 2026 collaboration revenue, but its net loss widened to $50.1 million. The nearest operational catalyst is the planned investigational new drug application for IAM-C1 in the fourth quarter of 2026, followed by potential analyst initiations after the quiet period. The 180-day lock-up is expected to expire on 12 April 2027, while registration rights covering approximately 32.3 million shares create a substantial longer-term overhang relative to the 9.4-million-share IPO. The main risk is that the market continues to reduce AI-biotechnology valuations before Iambic produces clinical evidence capable of validating its platform.
Read more about IAM.US on the TFOS platform
City Therapeutics (CTY)
IPO 16 October 2026
The company
City Therapeutics is a clinical-stage biotechnology company developing RNA-interference medicines with tissue-selective delivery. Its lead programs include CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt and other retinal diseases and CITY-TFR2 for anemia associated with chronic disease. The company also has research collaboration agreements with Bausch + Lomb.
Competitors and market
City Therapeutics competes with established anticoagulants and biotechnology companies developing RNA-based therapies for cardiovascular, ophthalmic and hematological diseases. The company is attempting to differentiate itself through selective delivery that could improve efficacy and reduce unwanted systemic effects. Investor demand was strong enough for the offering to increase from approximately 9.7 million to 11.1 million base shares, followed by the full exercise of the underwriters’ option. The stock has retained most of its first-day gain, indicating continued investor interest in RNA-interference platforms despite the company’s early clinical stage.
Price action
- IPO price: $18.00 per share
- Final offering size: 12,777,777 shares, including 1,666,666 shares from the full exercise of the underwriters’ option
- Gross proceeds: approximately $230 million
- First day, 16 October: opened at $23.00 and closed at $22.40, approximately 24.4% above the IPO price
- Latest verified price: $22.14 at the 29 October close, up 2.3% for the session
- Performance from IPO price: approximately +23.0%
- Performance from first-day close: approximately −1.2%
- Market capitalization: approximately $1.1 billion
Chart: trade.tfos.com/charts/CTY.US
City Therapeutics consolidated after its strong debut and remained close to the first-day closing price, giving CTY the most stable performance among the companies that have traded for about two weeks.
Conclusion and what to expect
City Therapeutics carries a valuation of approximately $1.1 billion despite remaining in Phase 1 and reporting a trailing net loss of $87.67 million. The premium reflects investor expectations for its RNA-interference platform, tissue-selective delivery technology and diversified pipeline. Approximately three-quarters of the company’s shares remain restricted, with the 180-day IPO lock-up expected to expire on 14 April 2027. Near-term attention will focus on analyst initiations in November and progress with CITY-FXI, while any clinical setback or broader decline in RNA-therapy valuations could weigh on the shares.
Read more about CTY.US on the TFOS platform
Lycia Therapeutics (LYCA)
IPO 23 October 2026
The company
Lycia Therapeutics is a clinical-stage biotechnology company developing medicines that use targeted protein degradation to address immunological diseases. Its lead candidate, LCA-0061, produced a mean maximum immunoglobulin E reduction of 96% after a single 70 mg dose in preliminary Phase 1 results. Additional LCA-0061 data and initial clinical data for LCA-0321 are expected in 2027.
Competitors and market
Lycia competes with established allergy and autoimmune treatments as well as biotechnology companies developing antibodies, small molecules and protein-degradation therapies. Its early IgE biomarker results have created expectations that the platform could deliver deep and durable biological effects after limited dosing. Investor demand was strong enough for the company to increase the offering and sell the entire underwriters’ option. The first-day gain shows strong interest, although the subsequent volatility reflects how much of the valuation rests on assets that remain in Phase 1.
Price action
- IPO price: $18.00 per share, the top of its range
- Initial offering: 17,640,000 shares for gross proceeds of approximately $317.5 million
- Final offering size: 20,286,000 shares after full exercise of the underwriters’ option
- Final gross proceeds: approximately $365.1 million
- First day, 23 October: closed at $30.00, approximately 66.7% above the IPO price
- First-day range: $22.19–36.49
- Latest verified price: $27.73 at the 29 October close, up 10.7% for the session
- Performance from IPO price: approximately +54.1%
- Performance from first-day close: approximately −7.6%
- Market capitalization at the latest price: approximately $1.4 billion
Chart: trade.tfos.com/charts/LYCA.US
Lycia produced the strongest debut and post-IPO return in the group, although the shares have already shown large daily movements. The latest price remained well above the offer price but below the first-day high.
Conclusion and what to expect
Lycia’s approximately $1.4 billion valuation is supported primarily by a preliminary biomarker result rather than mature clinical evidence. With 31 employees at the IPO and no major new data expected until 2027, the valuation rests on early results. A customary 180-day lock-up from the 22 October prospectus would end around 20 April 2027. Over the coming months, investors will focus on the durability and clinical relevance of the IgE reduction, while the thin float may keep volatility elevated.
Read more about LYCA.US on the TFOS platform
Prices and performance figures in the text are as at the dates stated; panels are TFOS platform snapshots of 30 October 2026 and can show later prices. Marketing communication, not independent investment research and not financial advice. Past performance is not a guide to future results. Turlov Family Office Securities (Pty) Ltd is an authorised FSP (52874).